Laksheeta Johari

While the space has traditionally been dominated by smaller biotechs, that may be changing.

FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur.

Limited patient populations require sponsors to adapt their practices when working in the rare disease space.

RDEP is a sign that regulators acknowledge that rare disease is a unique space that requires special attention.